China Mengniu Dairy Company (2319) H2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2025 earnings summary
27 Mar, 2026Executive summary
Full-year revenue for 2025 was RMB 82.24 billion, down 7.3% year-over-year, with gross profit margin rising 0.3 points to 39.9% and operating profit at RMB 6.56 billion (8.0% margin).
Adjusted profit attributable to owners was RMB 3.96 billion, while net profit attributable to owners surged 1,378.9% to RMB 1.55 billion due to lower impairment provisions.
EBITDA margin rose 2.7ppt to 7.7% year-over-year, with EBITDA at RMB 6,362.1 million.
Strategic focus on product innovation, channel optimization, international expansion, and digital transformation.
Liquid milk business remained under pressure but showed stabilization and improvement in the second half.
Financial highlights
Gross profit was RMB 32,808 million, down from RMB 35,090.4 million in 2024.
Selling expenses fell 6.5% to RMB 21.59 billion, but selling and administrative expense ratios rose slightly due to negative operating leverage.
Operating cash flow reached a record RMB 8,750.5 million, with free cash flow at RMB 6.3 billion.
CapEx further reduced to RMB 2,494.5 million, a 30.4% decrease year-over-year.
Dividend per share increased to RMB 0.520, totaling RMB 2,017.0 million, with a three-year shareholder return plan.
Outlook and guidance
Industry stabilization and policy support expected to boost dairy consumption and recovery.
Focus on digital intelligence transformation, R&D innovation, channel upgrading, and brand-led growth.
Plans to accelerate product innovation, expand into lower-tier markets, and enhance omni-channel capabilities.
High-quality protein and functional nutrition products to be launched soon.
2026 positioned as a critical year for strategic execution and supply-demand balance.
Latest events from China Mengniu Dairy Company
- Revenue and profit declined, but margins improved and a major share buyback was announced.2319
H1 202423 Jan 2026 - Revenue fell 10.1% as net profit plunged on impairments, but margins and dividends rose.2319
H2 202421 Dec 2025 - Revenue fell 6.9% but margins improved; net profit dropped 16.4% on associate losses.2319
H1 202523 Nov 2025